NSE · GKSL · Healthcare
Gujarat Kidney & Super Speciality Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹9 Cr with net profit ₹2 Cr — a 22.08% net margin, versus 14.83% the period before.
Shareholding
As of 2026-06-30
- Promoter71.45%
- Public23.1%
- FII4.88%
- DII0.56%
18,301 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.86× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #29 of 85 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,25,042 Cr | 59.43 | 13.21 | 20.48% | 7.91% |
| Max Healthcare Institute Ltd. | ₹99,764 Cr | 66.64 | 9.35 | 13.42% | 16.73% |
| Manipal Health Enterpri Limited | ₹93,997 Cr | 100.22 | 5.72 | 10.59% | 7.81% |
| Fortis Healthcare Ltd. | ₹65,704 Cr | 61.59 | 6.63 | 10.53% | 11.02% |
| Aster DM Quality Care Ltd. | ₹64,504 Cr | 166.29 | 15.35 | 8.48% | 6.54% |
| Narayana Hrudayalaya Ltd. | ₹37,839 Cr | 43.9 | 8.34 | 17.76% | 9% |
| Global Health Limited | ₹37,766 Cr | 65.97 | 9.54 | 14.05% | 11.88% |
| Krishna Institute of Medical Sciences Ltd. | ₹32,200 Cr | 154.26 | 8.6 | 10.74% | 4.85% |
| Dr. Lal Path Labs Ltd. | ₹31,819 Cr | 56.57 | 12.67 | 20.13% | 18.75% |
| Poly Medicure Ltd. | ₹17,239 Cr | 53.87 | 5.57 | 10.37% | 15.77% |
| Gujarat Kidney & Super Speciality Ltd.(this company) | ₹1,359 Cr | 85.74 | 5.38 | 6.14% | 15.67% |
AI analysis
AI-generated · google/gemini-2.5-flashGujarat Kidney & Super Speciality Ltd. (GKSL) has a market capitalization of Rs 1012 Cr. The company reported revenue of Rs 40.4 Cr and an EPS of Rs 1.67. Its latest ROE stands at 51.7% and ROCE at 8.20%.
Positives
- +Promoter holding is high at 71.45% as of June 30, 2026.
- +The Return on Equity (ROE) is 51.7%.
- +The debt-to-equity ratio is 0.39.
Negatives
- −The Price-to-Earnings (PE) ratio is 0, which may indicate no recent earnings or negative earnings.
- −FII holding decreased from 10.47% in Dec 2025 to 4.88% in Jun 2026.
- −DII holding decreased from 1.67% in Dec 2025 to 0.56% in Jun 2026.
- −The number of shareholders decreased from 27,783 in Dec 2025 to 18,301 in Jun 2026.
Financial Performance
Gujarat Kidney & Super Speciality Ltd. reported total revenue of Rs 40.4 Cr. The company's EPS is Rs 1.67. The latest annual net profit data available shows a net profit of Rs 1.37 Cr for Mar 2026, which was preceded by Rs 2.33 Cr in Dec 2025 and Rs 2.3 Cr in Sept 2025. Quarterly net profit for Mar 2026 was Rs 5.04 Cr, following Rs 2.94 Cr in Dec 2025 and Rs 2.67 Cr in Sept 2025.
Profitability & Returns
The company's Return on Equity (ROE) is 51.7% and Return on Capital Employed (ROCE) is 8.20%. The Price-to-Earnings (PE) ratio is 0. The book value per share is Rs 4.56. The latest annual EBITDA for Mar 2026 was Rs 1.35 Cr, with quarterly EBITDA for Mar 2026 at Rs 5.5 Cr.
Balance Sheet
The debt-to-equity ratio for Gujarat Kidney & Super Speciality Ltd. is 0.39. Further information regarding the company's assets and detailed liabilities is not available in the provided data.
Ownership & Pledges
There are no promoter shares reported as pledged.
Regulatory & Surveillance
No information regarding the company being under any surveillance measure is available in the provided data. The number of shareholders as of June 30, 2026, was 18,301, a decrease from 27,783 shareholders on December 31, 2025.
Data as of — price: 2026-09-17 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Gujarat Kidney & Super Speciality Ltd.share price & fundamentals